Real-world study results back switch to Remsima

Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to biosimilar infliximab from originator drug, Johnson & Johnson’s (NYSE: JNJ) blockbuster rheumatoid arthritis drug Remicade (infliximab).

The studies, presented at the 11th Congress of the European Crohn’s and Colitis Organization (ECCO), further support the appropriate switching of patients to Celltrion’s (Kosdaq: 068270) Remsima and build on the wealth of real-world evidence of its safety and efficacy accumulated since its launch a year ago.

As physician experience with biosimilar infliximab has grown, so has confidence in monoclonal antibody biosimilars.